News & Updates

Letrozole outperforms clomiphene citrate for ovulation induction

06 Feb 2023

The use of letrozole for inducing ovulation in women with infertility and polycystic ovarian syndrome (PCOS) appears to yield improvements in ovulation, pregnancy, and live-birth rates as compared with clomiphene citrate, according to a study.

Letrozole outperforms clomiphene citrate for ovulation induction

06 Feb 2023

Original New Drug Application Approvals by US FDA (16-31 January 2023)

31 Jan 2023

New drug applications approved by US FDA as of 16-31 January 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-31 January 2023)

31 Jan 2023

Ospemifene improves vaginal microbiome of women with vulvovaginal atrophy

29 Jan 2023

Women with vulvovaginal atrophy exhibit a less favourable vaginal microbiome than healthy postmenopausal women, but ospemifene may restore vaginal health by reducing potentially harmful bacteria, as shown in a study.

Ospemifene improves vaginal microbiome of women with vulvovaginal atrophy

29 Jan 2023

Are children conceived with assisted technologies at risk for cardiometabolic events?

27 Jan 2023

Children conceived by their parents through non-in vitro fertilization fertility treatment show no metabolic difference from those conceived spontaneously, according to a study.

Are children conceived with assisted technologies at risk for cardiometabolic events?

27 Jan 2023

Diminished ovarian reserve linked to pre-eclampsia, placental vascular lesions

26 Jan 2023

Among pregnant women who conceived via in vitro fertilization (IVF), diminished ovarian reserve appears to contribute to a higher incidence of pre-eclampsia and multiple placental vascular lesions of foetal origin, as reported in a study.

Diminished ovarian reserve linked to pre-eclampsia, placental vascular lesions

26 Jan 2023

NAFLD, regardless of obesity status, ups risk of adverse pregnancy outcomes

26 Jan 2023

Women with nonalcoholic fatty liver disease (NAFLD), despite having a normal weight, remains at greater risk of adverse pregnancy outcomes, reveals a study.

NAFLD, regardless of obesity status, ups risk of adverse pregnancy outcomes

26 Jan 2023

PCOS does not make COVID-19 worse for women

25 Jan 2023

In women who have contracted COVID-19, the presence of polycystic ovary syndrome (PCOS) does not appear to drive the risk of increased disease severity, according to a study.

PCOS does not make COVID-19 worse for women

25 Jan 2023

Trastuzumab deruxtecan confers hope as second-line therapy for HER2+ mBC

20 Jan 2023 by

Updated results of the DESTINY-Breast03 trial, presented at SABCS 2022, showed that in patients with HER2+ metastatic breast cancer, second-line treatment with trastuzumab deruxtecan conferred better survival benefits than treatment with trastuzumab emtansine.

Trastuzumab deruxtecan confers hope as second-line therapy for HER2+ mBC

20 Jan 2023

Signs of heavy menstrual bleeding often missed; standardized criteria for assessment needed

20 Jan 2023 by

Healthcare professionals (HCPs) and women themselves may overlook the signs of heavy menstrual bleeding, with most HCPs failing to recognize the key indicators for bleeding disorders and perform assessments for patients with heavy menstrual bleeding, according to a study presented at ASH 2022.

Signs of heavy menstrual bleeding often missed; standardized criteria for assessment needed

20 Jan 2023

PPI exposure during early pregnancy poses no excess risk of congenital malformations

15 Jan 2023

The use of proton pump inhibitors (PPIs) during early pregnancy does not appear to put infants at increased risk of congenital malformations, as reported in a study. However, there seems to be a small risk increase for major congenital malformations and congenital heart defects.

PPI exposure during early pregnancy poses no excess risk of congenital malformations

15 Jan 2023

News & Updates

Filter by Specialty:

Specialty:

Letrozole outperforms clomiphene citrate for ovulation induction

Letrozole outperforms clomiphene citrate for ovulation induction

Original New Drug Application Approvals by US FDA (16-31 January 2023)

Original New Drug Application Approvals by US FDA (16-31 January 2023)

Ospemifene improves vaginal microbiome of women with vulvovaginal atrophy

Ospemifene improves vaginal microbiome of women with vulvovaginal atrophy

Are children conceived with assisted technologies at risk for cardiometabolic events?

Are children conceived with assisted technologies at risk for cardiometabolic events?

Diminished ovarian reserve linked to pre-eclampsia, placental vascular lesions

Diminished ovarian reserve linked to pre-eclampsia, placental vascular lesions

NAFLD, regardless of obesity status, ups risk of adverse pregnancy outcomes

NAFLD, regardless of obesity status, ups risk of adverse pregnancy outcomes

PCOS does not make COVID-19 worse for women

PCOS does not make COVID-19 worse for women

Trastuzumab deruxtecan confers hope as second-line therapy for HER2+ mBC

Trastuzumab deruxtecan confers hope as second-line therapy for HER2+ mBC

Signs of heavy menstrual bleeding often missed; standardized criteria for assessment needed

Signs of heavy menstrual bleeding often missed; standardized criteria for assessment needed

PPI exposure during early pregnancy poses no excess risk of congenital malformations

PPI exposure during early pregnancy poses no excess risk of congenital malformations